ਹੱਡੀਆਂ ਦੀ ਸਿਹਤ ਅਤੇ ਓਸਟੀਓਪੋਰੋਸਿਸ

This is the clinical evidence summary written for health professionals. It is technical, and it lists the research this page was built from. You do not need to read it to understand your treatment or to make a decision about it.

Overview¶

• A bone density based aging model may facilitate and support the development of precision medicine strategies in osteoporosis prevention and management [1].
• Optimizing teriparatide administration timing may guide personalized dosing strategies to enhance bone formation and reduce fracture risk in osteoporosis [2].
• Natural traditional Chinese medicine products provide a theoretical and experimental basis for the development of new drugs and the improvement of osteoporosis management [3].
• Sequential anabolic-to-anti-resorptive therapy may inform treatment guidelines for high-risk postmenopausal populations [4].
• Acupuncture shows encouraging efficacy in improving symptoms of primary osteoporosis as a physical intervention in clinical practice [5].
• Machine learning application to hand radiographs represents a possible step toward more accessible, cost-effective, automated diagnosis and earlier treatment of osteoporosis/osteopenia [6].
• Low rates of osteoporotic pharmacotherapy were seen in patients who had femoral neck fractures despite established guidelines [7].
• Patients with osteoporosis may experience a higher incidence of medical complications within the 90-day global period than nonosteoporotic patients following rotator cuff repair [8].
• Patients with decreased bone mineral density can still achieve excellent 2-year outcomes after arthroscopic rotator cuff repair [9].
• Osteoporosis is a risk factor for complications and reoperations at 1 and 3 years after arthroscopic rotator cuff repair [11].
• Osteoporosis should not be considered a contraindication to arthroscopic rotator cuff repair given overall low complication rates [11].
• Continuous bone cement and standardized treatment for osteoporosis were guarantees of good clinical outcomes for percutaneous vertebroplasty [12].
• Injected bone cement >5.5 ml might be a guarantee of good clinical outcomes for percutaneous vertebroplasty [12].

How It Works¶

• Bone density-based aging models can facilitate and support the development of precision medicine strategies in osteoporosis prevention and management [1].
• Acupuncture shows encouraging efficacy in improving symptoms of primary osteoporosis, supporting its use as a physical intervention in clinical practice [5].
• Machine learning applied to hand radiographs represents a possible step toward more accessible, cost-effective, automated diagnosis and earlier treatment of osteoporosis/osteopenia [6].
• Low rates of osteoporotic pharmacotherapy are observed in patients who have sustained femoral neck fractures despite established guidelines [7].
• Patients with osteoporosis may experience a higher incidence of medical complications within the 90-day global period following rotator cuff repair than nonosteoporotic patients [8].
• Patients with decreased bone mineral density can still achieve excellent 2-year outcomes following arthroscopic rotator cuff repair [9].
• Current machine learning-based prediction models for postmenopausal osteoporosis without fractures demonstrate good discriminative ability but are generally characterized by a high risk of bias, a notable lack of calibration performance evaluation, and insufficient validation of clinical utility [10].
• Genetically modified stem cell therapy is a safe and effective method that can significantly improve bone mineral density and bone volume/total volume in animal models of osteoporosis [13].
• The prevalence of osteoporosis among postmenopausal women hospitalized for fractures in China is 76.9%, with prolonged menopause, vertebral fractures, and recent fracture history identified as key risk profiles [14].
• Obesity-associated dyslipidemia drives bone mineral density loss partly through inflammation-mediated pathways, with key inflammatory cytokines significantly mediating lipid metabolism's impact on bone health [16].
• Bone mineral density alone cannot predict early migration of tibial baseplates in cementless total knee arthroplasty [17].

What the Evidence Shows¶

Risk Prediction and Screening¶

• A bone density-based aging model may facilitate precision medicine strategies in osteoporosis prevention and management [1].

Pharmacologic and Non-Pharmacologic Therapies¶

• The efficacy of acupuncture in improving the symptoms of primary osteoporosis is encouraging for its use in clinical practice as a physical intervention [5].
• Genetically modified stem cell therapy is a safe and effective method that can significantly improve bone mineral density (BMD) and bone volume/total volume (BV/TV) in animal models of osteoporosis [13].
• Jintiange capsules are a good choice for patients with osteoporosis for relieving pain, improving BMD, improving activity function, and improving gait and preventing fracture [18].

Perioperative Outcomes and Complications¶

• Despite established guidelines, low rates of osteoporotic pharmacotherapy were seen in patients who had femoral neck fractures [7].
• In osteopenic and osteoporotic patients undergoing total joint arthroplasty, rates of 2- and 5-year postoperative complications were low and similar among patients who used proton pump inhibitors perioperatively and those who did not [15].
• Bisphosphonate use in patients who have osteoporosis did not decrease the risk of periprosthetic fracture following total knee arthroplasty, but significantly lowered the incidence of all-cause revision at 2 years [20].

Surgical Efficacy and Technical Factors¶

• Osteoporosis should not be considered a contraindication to arthroscopic rotator cuff repair [11].
• Continuous bone cement and standardized treatment for osteoporosis were guarantees of good clinical outcomes for percutaneous vertebroplasty, and injected bone cement >5.5 ml might be a guarantee [12].

Practical Considerations¶

• Bone density-based aging models may facilitate precision medicine strategies in osteoporosis prevention and management [1].
• Machine learning applied to hand radiographs represents a step toward more accessible, cost-effective, automated diagnosis and earlier treatment of osteoporosis/osteopenia [6].
• Low rates of osteoporotic pharmacotherapy were observed in patients with femoral neck fractures despite established guidelines [7].
• Patients with osteoporosis may experience a higher incidence of medical complications within the 90-day global period following rotator cuff repair compared to nonosteoporotic patients [8].
• Patients with decreased bone mineral density can achieve excellent 2-year outcomes after arthroscopic rotator cuff repair [9].
• Machine learning-based prediction models for postmenopausal osteoporosis without fractures demonstrate good discriminative ability but are characterized by a high risk of bias, a notable lack of calibration performance evaluation, and insufficient validation of clinical utility [10].
• Continuous bone cement and standardized treatment for osteoporosis are guarantees of good clinical outcomes for percutaneous vertebroplasty [12].
• Injected bone cement volume greater than 5.5 ml might be a guarantee of good clinical outcomes for percutaneous vertebroplasty [12].
• The prevalence of osteoporosis among postmenopausal women hospitalized for fractures in China is 76.9% [14].
• Prolonged menopause, vertebral fractures, and recent fracture history are key risk profiles for osteoporosis in postmenopausal women hospitalized for fractures [14].
• Rates of 2- and 5-year postoperative complications in osteopenic and osteoporotic patients undergoing total joint arthroplasty were low and similar among those who used perioperative proton pump inhibitors and those who did not [15].

Key Evidence¶

• [L3] This approach may facilitate and support the development of precision medicine strategies in osteoporosis prevention and management. [1] (10.1186/s12891-025-09298-0)
• [L2] This trial is expected to provide crucial insights into optimizing teriparatide administration timing, potentially guiding personalized dosing strategies to enhance bone formation and reduce fracture risk in osteoporosis. [2] (10.1186/s13018-025-06083-6)
• [L4] This paper summarises recent research progress on natural TCM products in preventing and treating osteoporosis and provides a theoretical and experimental basis for the development of new drugs and the improvement of osteoporosis management. [3] (10.1186/s13018-025-05879-w)
• [L1] This sequential anabolic-to-anti-resorptive therapy may inform treatment guidelines for high-risk postmenopausal populations. [4] (10.1186/s13018-025-06040-3)
• [L1] The current evidence suggests that the efficacy of acupuncture in improving the symptoms of primary osteoporosis is encouraging for its use in clinical practice as a physical intervention. [5] (10.1186/s13018-025-05513-9)
• [L2] The findings represent a possible step toward more accessible, cost-effective, automated diagnosis and therefore earlier treatment of osteoporosis/osteopenia. [6] (10.1016/j.jhsa.2024.09.008)
• [L3] Despite established guidelines, low rates of osteoporotic pharmacotherapy were seen in patients who had femoral neck fractures. [7] (10.1016/j.arth.2025.07.028)
• [L3] In addition, patients with osteoporosis may experience a higher incidence of medical complications within the 90-day global period than nonosteoporotic patient. [8] (10.1016/j.xrrt.2026.100723)
• [L3] Patients with decreased bone mineral density can still achieve excellent 2-year outcomes. [9] (10.1016/j.jse.2025.02.011)
• [L1] Current machine learning-based prediction models for postmenopausal osteoporosis without fractures demonstrate good discriminative ability but are generally characterized by a high risk of bias, a notable lack of calibration performance evaluation, and insufficient validation of clinical utility. [10] (10.1186/s12891-025-09385-2)
• [L3] Overall rates of complication were low and osteoporosis should not be considered a contraindication to arthroscopic RCR. [11] (10.1016/j.jseint.2026.101678)
• [L3] Continuous bone cement and standardized treatment for osteoporosis were guarantees of good clinical outcomes for PVP, and injected bone cement >5.5 ml might be a guarantee. [12] (10.1186/s12891-024-08153-y)
• [L1] Genetically modified stem cell therapy is a safe and effective method that can significantly improve the BMD and BV/TV in animal models of osteoporosis. [13] (10.1186/s12891-025-08507-0)
• [L4] This study reveals an alarmingly high prevalence (76.9%) of osteoporosis among postmenopausal women hospitalized for fractures in China, identifying prolonged menopause, vertebral fractures, and recent fracture history as key risk profiles. [14] (10.1186/s12891-026-09517-2)
• [L3] In osteopenic and osteoporotic patients undergoing TJA, rates of 2- and 5-year postoperative complications were low and similar among patients who used PPIs perioperatively and those who did not. [15] (10.1016/j.arth.2025.07.067)
• [L4] Obesity-associated dyslipidemia drives BMD loss partly through inflammation-mediated pathways, with key inflammatory cytokines significantly mediating lipid metabolism's impact on bone health. [16] (10.1186/s12891-026-09576-5)
• [L4] Our results suggest that BMD alone cannot predict early migration of tibial baseplates. [17] (10.1016/j.arth.2026.03.014)
• [L1] In terms of relieving pain, improving BMD, improving activity function, and improving gait and preventing fracture, JTG is a good choice for patients with osteoporosis (OP). [18] (10.1186/s12891-025-08694-w)
• [L3] While bisphosphonate use in patients who have osteoporosis did not decrease the risk of periprosthetic fracture, it did significantly lower the incidence of all-cause revision at 2 years. [20] (10.1016/j.arth.2024.11.004)

References¶

[1] Unveiling risk factors and predicting osteoporosis through bone density based aging model: a community-based cohort in Guangdong, China. BMC Musculoskeletal Disorders. 2025. DOI: 10.1186/s12891-025-09298-0

[2] Timing optimization of teriparatide dosing for postmenopausal osteoporosis: a randomized controlled trial. Journal of Orthopaedic Surgery and Research. 2025. DOI: 10.1186/s13018-025-06083-6

[3] Natural traditional Chinese medicine products: emerging therapeutic targets for the treatment of osteoporosis. Journal of Orthopaedic Surgery and Research. 2025. DOI: 10.1186/s13018-025-05879-w

[4] Effectiveness of anabolic and anti-resorptive agents for preventing postmenopausal osteoporosis fractures: a systematic review and network meta-analysis. Journal of Orthopaedic Surgery and Research. 2025. DOI: 10.1186/s13018-025-06040-3

[5] Efficacy of acupuncture for primary osteoporosis: a systematic review and meta-analysis of randomized controlled trials. Journal of Orthopaedic Surgery and Research. 2025. DOI: 10.1186/s13018-025-05513-9

[6] Application of Machine Learning to Osteoporosis and Osteopenia Screening Using Hand Radiographs. The Journal of Hand Surgery. 2025. DOI: 10.1016/j.jhsa.2024.09.008

[7] A Missed Opportunity? Osteoporosis Treatment Following Femoral Neck Fractures: Reducing the Risk of Secondary Hip Fracture. The Journal of Arthroplasty. 2026. DOI: 10.1016/j.arth.2025.07.028

[8] Impact of osteoporosis on post-operative outcomes following rotator cuff repair. JSES Reviews, Reports, and Techniques. 2026. DOI: 10.1016/j.xrrt.2026.100723

[9] No difference in 2-year outcomes of arthroscopic rotator cuff repair in patients with osteoporosis. Journal of Shoulder and Elbow Surgery. 2025. DOI: 10.1016/j.jse.2025.02.011

[10] Risk prediction models for postmenopausal osteoporosis: a systematic review and meta-analysis study. BMC Musculoskeletal Disorders. 2026. DOI: 10.1186/s12891-025-09385-2

[11] Osteoporosis is a risk factor for complications and reoperations at 1 and 3 years after arthroscopic rotator cuff repair. JSES International. 2026. DOI: 10.1016/j.jseint.2026.101678

[12] Continuity and volume of bone cement and anti osteoporosis treatment were guarantee of good clinical outcomes for percutaneous vertebroplasty: a multicenter study. BMC Musculoskeletal Disorders. 2025. DOI: 10.1186/s12891-024-08153-y

[13] Genetically modified stem cells for osteoporosis: a systematic review and meta-analysis of preclinical studies. BMC Musculoskeletal Disorders. 2025. DOI: 10.1186/s12891-025-08507-0

[14] How prevalent is osteoporosis in a high-risk subgroup? A multicenter study of postmenopausal women hospitalized for fractures in China. BMC Musculoskeletal Disorders. 2026. DOI: 10.1186/s12891-026-09517-2

[15] Effects of Perioperative Proton Pump Inhibitor Use on Outcomes of Total Joint Arthroplasty Patients Who Have Osteoporosis and Osteopenia. The Journal of Arthroplasty. 2026. DOI: 10.1016/j.arth.2025.07.067

[16] Perioperative inflammatory cytokines nursing screening test indicate the link between dysregulated lipid metabolism and reduced bone mineral density in obese osteoporosis patients: a retrospective study. BMC Musculoskeletal Disorders. 2026. DOI: 10.1186/s12891-026-09576-5

[17] Stable Fixation in Cementless Total Knee Arthroplasty Even for Low Local Bone Mineral Density. The Journal of Arthroplasty. 2026. DOI: 10.1016/j.arth.2026.03.014

[18] The effect of Jintiange capsules on pain in patients with primary osteoporosis: a systematic review and meta-analysis. BMC Musculoskeletal Disorders. 2025. DOI: 10.1186/s12891-025-08694-w

[20] Bisphosphonate Use in Patients Who Have Osteoporosis Does Not Increase the Risk of Periprosthetic Fracture Following Total Knee Arthroplasty. The Journal of Arthroplasty. 2025. DOI: 10.1016/j.arth.2024.11.004